Company announcement – No. 53 / 2024

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, December 25, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file(s).

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnership agreements with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contact:

Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com 

Adam Lange (Investors)
Investor Relations Officer
Email: alange@zealandpharma.com 

Anna Krassowska, PhD (Media and Investors)
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com 

Attachment

• 20241225 - Leonard Kruimer - Purchase of shares